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In rheumatoid arthritis (RA), various hematopoietic and non-hematopoietic cells present in
the synovial tissue secrete numerous inflammatory mediators including pro-inflammatory
cytokines critical for the induction of chronic joint inflammation and bone destruction.
Fibroblast-like synoviocytes (FLSs) in the non-hematopoietic cell compartment are key
inflammatory cells activated in inflamed joints and driving the disease; yet how synovial
tissue inflammation is modulated by autoimmune T cells is not fully understood. In this
review, mainly based on recent findings with amousemodel of spontaneous autoimmune
arthritis, we discuss the mechanism of Th17-mediated synovial tissue inflammation;
that is, what environmental stimuli and arthritogenic self-antigens trigger arthritis, how
arthritogenic T cells initiate joint inflammation by stimulating FLSs, and how the cellular
sources of GM-CSF from lymphoid and tissue stromal cells in the synovium contribute
to the development of arthritis. We also highlight possible plasticity of Th17 cells toward
pathogenic GM-CSF producers, and the functional instability of regulatory T cells under
inflammatory conditions in RA joints.
Keywords: autoimmune arthritis, Th17, treg cells, rheumatoid arthritis, synovial inflammation, proinflammatory
cytokine
INTRODUCTION
Rheumatoid arthritis (RA), which afflicts 1% of the population worldwide, is a systemic
autoimmune disease characterized by chronic inflammation of the synovial tissue and joint
destruction (1). There is accumulating evidence that various types of immune cells (e.g., T cells,
B cells, macrophages, and neutrophils) with pro-inflammatory or anti-inflammatory potentials are
recruited into RA joints and play key roles for RA development and progress (1). Although the
molecular and cellular mechanisms of RA pathogenesis are still controversial, it is now generally
accepted that CD4+ T helper (Th) cells play a crucial role in disease manifestation of RA as
indicated by abundant infiltration of Th cells in RA joints, human leukocyte antigen (HLA)-DRB1
identified as the strongest disease risk gene for RA, and high efficacy of CTLA4-Ig treatment in RA
patients (1–3). On the other hand, it is evident that macrophage- and fibroblast-like synoviocye
(FLS)-derived inflammatory cytokines such as TNFα, IL-1, and IL-6 are abundant in RA synovial
fluid and involved in joint inflammation and destruction as well, illustrated by high effectiveness
of anti-cytokine therapies targeting TNFα and IL-6 in controlling disease activities (4, 5). However,
how Th cells interact withmacrophages and FLSs or even other immune cells to orchestrate chronic
synovial inflammation is poorly understood. In this review, we discuss how autoimmune Th17
cells instigate FLSs and innate lymphoid cells (ILCs) in the synovial tissue to initiate and maintain
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autoimmune arthritis in SKG mice (6), an animal model of
RA, how arthritogenic Th17 cells differentiate toward pathogenic
GM-CSF producing cells in RA, and how regulatory T (Treg) cells
become functionally unstable in inflamed RA joints.
TH CELL-DEPENDENT AUTOIMMUNE
ARTHRITIS IN SKG MICE
There are several mouse models of autoimmune arthritis that
have made significant contributions to our understanding of the
pathogenetic mechanisms of RA. For example, collagen-induced
arthritis (CIA) and K/BxN mice are highly dependent on the
generation of autoantibody against type II collagen and glucose-
6-phosphate isomerase, respectively, as the serum alone, without
cellular components, from arthritic mice is able to transfer the
disease into recipient mice (7–9). By contrast, self-reactive Th
cells, but not autoantibody, mediate joint inflammation in SKG
mice, making the mice a suitable model to understand how
autoimmune T cells initiate and mediate synovial inflammation.
The SKG strain of mice on the BALB/c background
spontaneously develops Th cell-mediated autoimmune arthritis
as a consequence of a recessive point mutation in the gene
encoding ζ-associated protein-70 (Zap-70), a key TCR-proximal
signaling molecule (6, 10). This mutation impairs positive
and negative selection of T cells in the thymus, leading
to the production of self-reactive CD4+ T cells including
arthritogenic Th cells and reduced thymic production of Treg
cells. The resulting autoimmune arthritis resembles human
RA in immunopathology, for example, in abundant infiltration
of Th cells into arthritic joints and active formation of
autoantibodies such as rheumatoid factor and anti-citrullinated
peptide antibodies (6, 10, 11). Spontaneous arthritis in SKG
mice occurs in a conventional environment, but not under the
specific-pathogen-free condition (10, 12). Yet arthritis can be
triggered by activating innate immunity via Toll-like receptors,
the Dectin pathway, or complement pathways, for example,
by injection of zymosan, a crude fungal extract containing β-
glucans. It is also induced by allowing homeostatic proliferation
of arthritogenic CD4+ T cells in lymphopenic mice such
as Rag2−/− mice (12, 13). Recently, we have identified 60S
ribosomal protein L23a (Rpl23a) as an arthritogenic self-
antigen in SKG mice by single-cell TCR repertoire analysis
of effector Th cells isolated from inflamed joints and then
screening arthritogenic potentials of isolated TCRs in retrogenic
mice expressing a single TCR. Moreover, autoantibody against
RPL23A was specifically detected in the sera from RA patients,
which further illustrates the similarity in the molecular basis
of the joint inflammation between SKG arthritis and human
RA (14). Additionally, SKG mice were reported to be a
disease model of spondylarthritis since they develop enthesitis,
dactylitis, unilateral uveitis, sacroiliac joint arthritis, and vertebral
inflammation together with peripheral joint arthritis, which are
the clinical features of spondylarthritis (15, 16).
Among Th cell subsets, we showed that IL-17-producing T
helper (Th17) cells played a key role in the development of
arthritis in SKG mice (17). Cell transfer of CD4+ T cells from
Il17a−/− SKG mice into T cell-deficient mice completely failed
to induce arthritis. Il6−/− SKG mice, which were impaired in
T cell differentiation into Th17 cells, hardly developed arthritis.
Although both Th1 and Th17 cells were detected in inflamed
joints of SKG mice, IFN-γ-deficiency did not ameliorate,
but rather exacerbated SKG arthritis because IFN-γ-deficiency
augmented the differentiation and pathogenic function of Th17
cells. Similar findings in IFN-γ-deficient or its receptor deficient
mice were alsomade in other Th17-mediated diseasemodels such
as CIA and experimental autoimmune encephalomyelitis (EAE),
a well-established murine model of multiple sclerosis (18, 19).
This anti-inflammatory effect of IFN-γ can be explained, at least
in part, by decreased expression of indoleamine 2,3 dioxygenase
(IDO), a catabolic enzyme responsible for kynurenine product
from tryptophan. IDO is expressed in various types of cells
including macrophages and dendritic cells (DCs) and is induced
during inflammation by IFN-γ or other inflammatory cytokines.
Increased levels of IFN-γ-mediated IDO expression in DCs in
inflamed tissues play a key role in immune regulation in part
by deprivation of local tryptophan, followed by activation of the
general control non-repressed 2 kinase pathway in responding
to T cells, leading to inhibition of activation and proliferation of
local T cells including pathogenic Th17 cells. By contrast, IFN-
γ deficiency downregulates IDO expression, which subsequently
allows pathogenic Th17 cells to further expand in the sites of
inflammation and augment autoimmune pathologies (20–23).
These findings taken together support SKG mice as a suitable
animal model to address how autoimmune T cells orchestrate
chronic joint inflammation (17).
INITIATION OF ARTHRITIS BY
INTERACTION BETWEEN
ARTHRITOGENIC TH17 CELLS AND
FIBROBLAST-LIKE SYNOVIOCYTES
The initiation of arthritis in SKG mice requires self-reactive
(arthritogenic) CD4+ T cells to differentiate into effector Th17
cells and migrate into the joints. As the mechanism of this
Th17 differentiation of self-reactive CD4+ T cells, they first
become activated in the periphery by strong recognition of
class II MHC/self-peptide complexes expressed by antigen-
presenting cells (APCs), and reciprocally stimulate APCs
to upregulate CD80/CD86 through CD40/CD40L interaction,
further enhancing the activation and proliferation of self-
reactive CD4+ T cells. The APCs thus stimulated secrete IL-
6, IL-1, and IL-23, which, together with local tissue-derived
TGFβ, drive the differentiation of naïve CD4+ T cells into
arthritogenic Th17 cells. The migration of the arthritogenic Th17
cells into the synovial tissue occurs in a chemokine-dependent
manner, in particular via the CCR6-CCL20 axis. That is, Th17
cells predominantly express CCR6, while activated FLSs secrete
CCL20, the ligand of CCR6, so that FLSs preferentially recruit
Th17 cells into the synovial tissue. In fact, anti-CCR6 blocking
monoclonal antibody significantly decreased the severity of
arthritis in SKG mice by inhibiting infiltration of Th17 cells into
the joints (24). Moreover, FLSs upregulate CCL20 expression
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in response to IL-17, IL-1, or TNFα, whereas IFN-γ or IL-
4 inhibits the expression (24). These observations illustrate an
important feed-forward interaction between Th17 cells and FLSs
in the initiation and augmentation of joint inflammation: once
arthritogenic Th17 cells are activated and recruited into the
joints to initiate inflammation, FLSs further increase CCL20
in response to IL-17 and other pro-inflammatory cytokines,
and accelerate the recruitment of Th17 cells to initiate and
augment arthritis (24). Activated FLSs interact not only with
Th17 cells, but also with other immune cells to establish chronic
synovial inflammation, for example, by enhancing secretion of
chemokines such as Cxcl1 and Cxcl5 to recruit neutrophils into
the joints (25). Interestingly, similar to these findings in SKG
mice, Th17 cells and synoviocytes in RA patients express CCR6
and CCL20, respectively, with a significant correlation between
the level of IL-17 and CCL20 in RA joints (24). Furthermore,
recent GWAS studies have identified the CCR6 gene as a
disease susceptibility gene locus of RA. These observations
collectively indicate the interaction between Th17 cells and FLSs
as a key mechanism for the development of synovial tissue
inflammation (26).
GM-CSF, A KEY MEDIATOR THAT
MAINTAINS CHRONIC JOINT
INFLAMMATION
Granulocyte macrophage colony-stimulating factor (GM-CSF)
from various sources in inflamed synovial tissues amplifies
chronic synovial inflammation. We have recently demonstrated
that GM-CSF from lymphoid and tissue-resident cells in the joint
is a key component for initiating and maintaining autoimmune
arthritis (25). GM-CSF has recently been highlighted as a
potent pro-inflammatory cytokine that activates monocytes and
macrophages, and is produced by various types of cells, for
example, fibroblasts, endothelial cells and T cells in response
to inflammatory stimuli (27). GM-CSF can be targeted for the
treatment of RA because it is abundant in RA synovium in
association with strong activation of synovial macrophages, and
active production of IL-6 and TNFα in RA joints (28, 29). In
addition,Csf2−/− SKGmice completely failed to develop arthritis
regardless of the presence of effector Th17 cells in the periphery,
indicating an indispensable role of GM-CSF in SKG arthritis (25).
GM-CSF was partly produced by effector Th17 cells in inflamed
joints; however, T-cell-derived GM-CSF—although it augmented
arthritis—was dispensable for the induction of arthritis, while
non-T cell-derived GM-CSF was indispensable. By generating
mixed bone marrow chimeras, we have identified radio-resistant
stromal cells including FLSs and synovial-resident ILCs as the
crucial source of GM-CSF. Indeed, the severity of arthritis in
the bone marrow chimeras was significantly reduced when GM-
CSF production was specifically inhibited or lost either in radio-
resistant stromal cells or ILCs. Re-stimulation with IL-17 induced
GM-CSF production from FLSs in vitro. Moreover, when Th
cells from wild-type SKG mice, but not Il17a−/− SKG mice,
were adoptively transferred into Rag2−/− mice, synoviocytes
significantly increased the expression of Csf2 together with Il6
and Ccl20. These observations when taken together imply that
IL-17 from effector Th17 cells migrating into the synovial tissue
stimulates FLSs to produce GM-CSF. A small number of ILCs
are present in healthy joints of SKG mice as well as other
healthy mouse strains; among them, GM-CSF-producing ILCs
have substantially expanded in inflamed joints. Interestingly,
a large proportion of these GM-CSF-producing synovial ILCs
possessed the features of the group 2 ILCs (ILC2s). For example,
they predominantly express GATA3 and/or IL-13, known as the
master transcription factor and a signature cytokine, respectively,
of ILC2s, and upregulated in vitro production of GM-CSF as well
as IL-5 and IL-13 in response to a combination of IL-2 and IL-
33 stimulation. In addition, these synovial ILCs highly express
Toll-like receptor 9 (Tlr9) and synergistically increase GM-CSF
production when stimulated by a combination of IL-33 and CpG
DNA, a ligand of TLR9, but not by CpG DNA alone. It is thus
likely that synovial ILCs may respond to signals from necrotic
cells in inflamed joints, such as alarmins and damage-associated
molecular patterns (DAMPs) including IL-33 and mitochondrial
DNA. These findings taken together indicate that, unlike FLSs,
synovial ILCs become activated, expand and increase GM-CSF
production by sensing environmental signals such as IL-2, IL-33,
and self-DNA, which could be derived from arthritogenic Th17
cells and damaged cells in inflamed joints (25).
Thus, in autoimmune arthritis in SKG mice, which is
fully dependent on Th17 cells, the key primary event in the
initiation of arthritis is the migration of Th17 cells into the
synovial tissue to instigate FLSs by IL-17 and to modulate
their inflammatory profiles. Following the initiation of arthritis,
arthritogenic Th17 cells together with FLSs and synovial ILCs
orchestrate an inflammatory cascade to amplify chronic joint
inflammation by GM-CSF from various sources subjected to
different immunological stimuli, resulting in the activation of
synovial macrophages and their abundant production of pro-
inflammatory cytokines such as IL-1, IL-6, and TNFα (Figure 1).
TH CELLS IN RHEUMATOID ARTHRITIS
Before the discovery of Th17 cells, RA was believed to be
a Th1-mediated autoimmune disease based on the classical
Th1/Th2 paradigm in autoimmunity. Indeed, IFN-γ+ Th cells
are abundant among CD4+ T cells in RA synovial fluid (SF)
(30, 31). However, the pathogenic roles of IFN-γ in RA were
unclear because the intervention of IFN-γ in clinical trials yielded
controversial results (32–37). After the discovery of Th17 cells
and their crucial roles in animal models of various autoimmune
diseases including autoimmune arthritis, the roles of IL-17, and
Th17 subset have been extensively studied in RA. However, SF of
RA contains only low levels of IL-17 and only a small number of
Th17 cells (38–41). Moreover, phase III clinical trials using IL-17
inhibitors in RA patients showed no significant benefit over the
currently approved biologic agents (42, 43). These clinical results
suggest that a single intervention of IL-17 may not be sufficient to
ameliorate chronic joint inflammation in RA. Recent studies on
the plasticity of Th17 cells in RA and juvenile idiopathic arthritis
(JIA) may provide a possible explanation for these observations.
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FIGURE 1 | Chronic joint inflammation mediated by FLSs and inflammatory immune cells in SKG arthritis. Arthritogenic Th17 cells migrate into synovial tissue and
initiate joint inflammation by stimulating FLSs via IL-17. Activated FLSs secrete various inflammatory mediators to recruit and expand various inflammatory immune
cells. At a chronic stage, FLSs, ILC2s, and Th17 cells produce GM-CSF to activate inflammatory monocytes to facilitate chronic joint inflammation.
That is, a substantial population of IFN-γ+ T cells in SF has been
reported to co-express CCR6 and CD161, the surface markers of
human Th17 cells, and therefore, Th17 cells may be converted to
a Th1-like phenotype via an intermediate state of IFN-γ+ IL-17+
T cells when they encounter an IL-12high environment, which is
seen in SF of RA and JIA (44, 45). Such phenotypic changes of
Th17 cells in RA joints may account for the failure of the clinical
trials using IL-17 inhibitors.
Ex-Th17 cells in RA joints seem to critically contribute to
the progress of RA, at least in part by producing GM-CSF (46).
The pathogenic role of GM-CSF in RA has been investigated
and recent clinical trials using GM-CSF inhibitors have shown
significant efficacy (47–50). It is thus likely that pathogenic Th17
cells may have different roles at different phases of RA: IL-17-
producing Th17 cells for the initiation in an early phase and
GM-CSF-producing ex-Th17 cells for chronic inflammation in
a later phase. Following the initiation of arthritis, the majority
of Th17 cells become IFN-γ+ ex-Th17 cells in response to
the IL-12-abundant environment in arthritic joints and begin
to actively produce GM-CSF together with other GM-CSF-
producing cells such as FLSs and synovial ILCs. A GM-CSF-
rich environment in SF results in the activation of synovial
macrophages and induction of abundant pro-inflammatory
cytokines such as IL-1, IL-6, and TNFα, leading to chronic
bone destruction. The plasticity of Th17 cells toward the Th1-
like phenotype is rarely observed in SKG arthritis model but
can be seen in other murine models of autoimmune disease
(25). For example, IL-17 fate mapping mice revealed that
highly pathogenic IFN-γ+ or GM-CSF+ T cells in the spinal
cord of EAE mice were exclusively originated from Th17 cells
(51). It is hoped that further elucidation of the molecular
mechanisms of Th17 plasticity in autoimmune models would
help to develop effective means for controlling pathogenic ex-
Th17 cells in RA.
The effect of TNFα signaling on pathogenic T cells has been
considered stimulatory, but the kinetics of Th17 cells in RA
patients after treatment with TNF inhibitors seems to be variable
(52). The ratio of Th17 cells to regulatory T (Treg) cells in RA
patients was significantly higher than that in healthy controls
(53). In vitro stimulation with TNFα directly and indirectly
facilitated Th17 differentiation, which was consistent with the
correlation of the therapeutic efficacy of TNF inhibitors in RA
patients with decreased Th17/Treg ratios in the peripheral blood
(54–57). However, in RA patients who were non-respondent
to treatment with TNF inhibitors, the frequency of Th17 cells
in their peripheral blood was paradoxically increased after
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the treatment (57, 58). The underlying mechanisms of this
paradoxical clinical outcome remain unclear, but it could be
due to distinct immunological effects of TNFα signaling via
TNF receptor 1 (TNFR1) and TNFR2 as well as inflammatory
cells expressing different levels of these receptors (52). For
example, specific ablation of TNFα signaling via TNFR1,
but not TNFR2, upregulated IL-12/IL-23 p40 expression in
macrophages driving Th17 responses (59). Similarly, monocytes
from non-responder RA patients, who showed increased Th17
responses after treatment with TNF inhibitors, produced more
IL-12/IL-23 p40 (58). These findings taken together suggest
that the therapeutic effects of TNF inhibitors on chronic joint
inflammation are variable in RA patients because of their
heterogenous cellular responses via TNFR1 and TNFR2 signaling
and variable compositions of synoviocytes and their expression of
the two receptors.
REGULATORY T CELLS IN RA
Treg cells expressing the transcription factor Foxp3 are
indispensable for maintaining immunological self-tolerance and
suppressing the development of various autoimmune diseases
including autoimmune arthritis (60). However, there are few
reports on interactions between Treg cells and FLSs, both in
human RA and animal models. Treg cells in autoimmune
arthritis have been discussed with regard to the instability and
impaired function of Treg cells under inflammatory conditions in
inflamed joints (61). Among pro-inflammatory cytokines, IL-6 is
a well-characterized cytokine that determines the balance of the
differentiation of Th17/Treg cells in the periphery (54, 62–64).
Indeed, the treatment of active RAwith tocilizumab, a humanized
anti-IL-6 receptor antibody, significantly reduced clinical disease
activity along with a significant decrease of Th17 cells and an
increase of Treg cells in frequency in the peripheral blood (65).
This indicates that the high levels of systemic IL-6 in RA patients
tip the balance toward the dominance of Th17 cells. Abundant IL-
6 in SF of RA largely produced by FLSs and synovial macrophages
may also influence the differentiation and expansion of bystander
Th cells infiltrating arthritic joints.
Immunomodulatory roles of TNFα in the stability and
suppressive functions of Treg cells remain controversial. The
defective function of Treg cells was initially reported under
TNFα-abundant environments as seen in the peripheral blood
and arthritic joints of RA, and several possible mechanisms have
been proposed. For example, high levels of TNFα may prevent
Treg function by inhibiting the formation of the immunological
synapse (IS) between Tregs and APCs. The dynamics of Protein
kinase C θ (PKC-θ) in IS appear to be reciprocally regulated
in effector T and Treg cells: the recruitment of PKC-θ to IS
was necessary for full activation of effector T cells whereas the
PKC-θ recruitment reduced suppressive activity of Treg cells.
Notably, high levels of TNFα enhanced PKC-θ recruitment to
IS in Treg cells and inhibited their suppression activity, while
PKC-θ blockade protected Treg cells from inactivation by TNFα
and restored suppressive function (66). In contrast, disc large
homolog 1 (Dlgh1), a scaffolding protein, was recruited to IS by
4-fold more in Treg cells than in effector T cells, which enhanced
suppressive function of Treg cells. Treg cells from active RA
patients or from healthy controls treated with TNFα showed
diminishedDlgh1 recruitment and reduced suppressive function.
In addition, silencing of Dlgh1 gene expression abrogated human
Treg cell function (67). Furthermore, the suppressive function
of Treg cells in the presence of TNFα was modulated by the
dephosphorylation at the Ser418 site of FOXP3 through protein
phosphatase 1 and in contrast, the treatment with anti-TNFα
antibodies restored Treg function in RA patients (68). These
findings collectively indicate that chronic inflammation inhibits
the suppressive function of Treg cells in RA in part due to
high levels of TNFα which modulate FOXP3 phosphorylation
as well as regulate the expression and shuttling of PKC-θ and
Dlgh1 in a Treg cell-intrinsic manner. However, this concept
was recently challenged. According to reports with different
experimental conditions, TNFα did not inhibit the suppressive
function of human Treg cells, but rather enhanced the expression
of CD25 and Foxp3 in the presence of IL-2, and further promoted
the proliferation and survival of Treg cells through the direct
effect of TNFα on TNFR 2 in a Treg-cell intrinsic manner
to control effector T cells (69, 70). The impact of TNFα on
effector T cells should also be considered as mentioned above,
and effector T subsets in TNF-abundant environments may be
more resistant to the suppression by Treg cells at least in part
through the costimulatory effects of TNFα on effector T cells.
Further investigation is necessary to reconcile this discrepancy.
CONCLUDING REMARK
Biological agents have brought a paradigm shift in RA treatment.
However, it still remains elusive how anti-cytokine agents
modulate inflammatory properties of T cells, FLSs, and ILCs
in the synovial tissue over the course of the treatments, and
how the treatments impact interactions between effector immune
cells and FLSs in chronic joint inflammation. Animal models
such as SKG mice are useful for addressing these issues.
Recent studies including our own have indeed revealed the
roles of anti-RPL23A autoantibody and GM-CSF commonly
found in SKG mice and RA patients. The studies have also
uncovered a previously unappreciated aspect of an inflammatory
cascade mediated by arthritogenic Th17 cells interacting with
hematopoietic and non-hematopoietic cells in the synovial
tissue. Further study will facilitate our understanding of the
molecular and cellular basis of chronic joint inflammation and
help to devise a new RA treatment with better specificity
and efficacy.
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